Market Distortions from the 340B Drug Pricing Program

Similar documents
THE GROWTH OF SPECIALTY PHARMACY

PHARMACY COMPLIANCE RISK AREAS FOR 2014

Legislative & Regulatory Update Brad Young, RxPlus Government Affairs

In its written comments on our draft report, CMS concurred with our recommendation.

The Oncology Drug Marketplace: Trends in Discounting and Site of Care

Assessing the Potential Revenue Impact to Oncology Practices under a Cancer Drug Therapy Bundled Reimbursement Model

Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA

Prescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director

The Value of Walgreens

July 30, VIA TO

Rx Watchdog Report Trends in Manufacturer Prices of Generic Prescription Drugs Used by Medicare Beneficiaries 2003 to 2007

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

How Mail-Servi. Prepared for

Jefferies Healthcare Conference. June 2016

PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS

Seasonal Flu Vaccine Offers

Update to HMO Drug Formulary Tier Definitions. February 8, 2018

What CEOs Don t Know about Health System Pharmacy

2015 Annual Convention

Pharmaceutical System in the UK

Section Processing

2

You Get What You Pay For The Unintended Consequences of Buy and Bill in Oncology

Changes to Texas Medicaid Hearing Services Benefits to Accompany PACT Transition

United States For Non-Dependence: An Analysis of the Impact of Opioid Overprescribing in America

Seasonal Flu Vaccine Offers 2014/15

Statement Of. The National Association of Chain Drug Stores. For. U.S. Senate Committee on Finance. Hearing on:

Insurance Guide For Dental Healthcare Professionals

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.

Physician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010

IMPACT OF DRUG REBATES ON YOUR PARTICIPANTS AND YOUR PLAN RISK PROFILE Indiana Health and Wellness Summit

EXECUTIVE SUMMARY ENSURING PATIENT ACCESS TO SAFE, EFFECTIVE AND AFFORDABLE PRESCRIPTION MEDICINES // 2

Seasonal Flu Vaccine Offers 2015/16

Seasonal Flu Vaccine Offers

Economic Analysis of the NY State Prescription Opioid Tax

Summary of Related Documentation Pennsylvania House Bill 1846 of 2014

MARCH Funding the Miracles: Best Practices for Managing Spinraza and Other Orphan Drugs Archimedes, LLC. All Rights Reserved

Questions and Answers on 2009 H1N1 Vaccine Financing

TRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE

MArch The 2014 Drug Trend Report Highlights

GAO BRAND-NAME PRESCRIPTION DRUG PRICING

FlexRx 6-Tier. SM Pharmacy Benefit Guide

Medicaid Managed Care Pharmacy Networks

Pharmacy Audit Recovery Guidelines

2019 Medicare Physician Fee Schedule Proposed Rule

Aligning Incentives and Designing Payment Systems to Promote Excellence in Cancer Care and Innovation

Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015

How are Adult Immunizations paid for in the United States?

taking at (Jan. 21, 2016) by Older 2016.pdf).

J.D. Power Reports: Pharmacy s Focus on Customer Satisfaction Sets the Bar for the Healthcare Industry

Medication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes

2017 Drug Trends Series

DIABETES TEST STRIPS REIMBURSEMENT REDUCTIONS TO INDEPENDENT PHARMACIES WILL NEGATIVELY IMPACT MEDICARE PATIENTS

Benefit: Hearing Services and Hearing Aid Devices

Using Decision Support to Promote Value Based Prescribing

9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance

STATE AND COMMUNITY MODELS FOR IMPROVING ACCESS TO DENTAL CARE FOR THE UNDERSERVED

DIRECTORY Pharmacy

DIRECTORY Pharmacy. Toll-Free , TTY 711

Pharmacies: Alternative Vaccine Provider

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

You should not go to an emergency room for vaccinations, since it is not an emergency service.

2017 Drug Trend Report Commercial Medicare Medicaid Exchanges

MEDICAL SCHEDULE OF BENEFITS

We see health care. differently. Comprehensive data Novel insights Transformative actions Lasting value

The Age of Audits. The Age of Audits Optometry has never been targeted has that changed? What would you do??? The Age of Audits DISCLAIMER

NCPA LTC Division Newsletter

Prescription Drugs. Medicare & Medicaid Briefings National Health Policy Forum February 22, Jim Hahn Congressional Research Service

VIGILANT GROUP BENEFITS PROGRAM. BENEFIT PLANS AT A GLANCE This summary provides a brief overview of the Vigilant Group

Myriad Genetics Fiscal Third-Quarter 2017 Earnings Call 05/02/2017

RETAIL BULK DIABETIC SUPPLY TOOL BOX

Distribution Partner Briefing: A Partnership for Profit. Welcome to Smartcool s information package for prospective channel partners.

COMMUNITY ONCOLOGY CONFERENCE

Spending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices

340B Audit Experiences from 2015: What We Learned From Over 50 Audits

11/12/2015 THE LATEST ON THE 340B FRONT AGENDA MEGA GUIDANCE RELEASED. Mega Guidance released. Audit update from HRSA. Maintaining compliance

Group Plan Summary FASNY

Prescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks

Update on Regulatory Changes. June 21, 2010

Agenda. CWCI: Background

THE LATEST ON THE 340B FRONT

Chapter 6: Healthcare Expenditures for Persons with CKD

Mount Prospect, Illinois

Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable.

REVIEW AND FREQUENTLY ASKED QUESTIONS (FAQ) 8/5/2015. Outline. Navigating the DSMT Reimbursement Maze in Todays Changing Environment

Benefit: Hearing Services and Hearing Aid Devices

Statement to the United States House of Representatives Committee on Small Business Subcommittee on Healthcare and Technology

Changes to the Eighth Edition

January 16, Dear Administrator Verma:

Perverse Reverse Price Competition: Average Wholesale Prices and Medicaid Pharmaceutical Spending

NALC Health Benefit Plan Consumer Driven Health Plan (CDHP) and Value Option Plan 2019 Prescription Benefits

Physician Dispensing: Latest Research From WCRI. November 17, 2017

CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID

How State Flex Coordinators Can Use the Financial Indicators in CAHMPAS

Individual Market Schedule of Benefits

Are Drug Prices Too High? If So, Why? Geoffrey Joyce, PhD University of Southern California

Chapter 15 Section 1

DIRECTORY Pharmacy

Transcription:

Market Distortions from the 340B Drug Pricing Program Adam J. Fein, Ph.D. www.drugchannels.net @DrugChannels The opinions and views expressed in this presentation are those of the author and may not reflect any opinion, position, or direction of the event sponsor. 1

340B Program Growing at Double-Digit Rates TOTAL PURCHASES MADE UNDER THE 340B DRUG PRICING PROGRAM Purchases at discounted 340B prices Estimated purchases at invoice prices 340B program: 22.8% per year Manufacturers net revenues: 5.1% per year $29.7 $24.9 $ billions $10.6 $11.1 $6.9 $7.2 $9.0 $13.9 $12.0 $18.5 $16.2 $19.3 2012 2013 2014 2015 2016 2017 Source: Drug Channels Institute analysis of data from Health Resources and Services Administration and IQVIA. Dollar figures in billions. Excludes sales made directly to healthcare institutions by manufacturers. Data for purchases at discounted prices show value of purchases at or below the discounted 340B ceiling prices. Data at invoice prices reflect DCI estimates. Growth rates show compound average growth rate. 2

Hospitals Charity Care Costs Have Dropped U.S. HOSPITALS, UNCOMPENSATED CARE COSTS, TOTAL VALUE AND SHARE OF EXPENSES, 2012 TO 2016 Uncompensated care costs ($ billions) As percentage of total expenses $45.9 $46.4 $42.8 6.1% 5.9% 5.3% $35.7 $38.3 4.2% 4.3% 2012 2013 2014 2015 2016 Source: Drug Channels Institute analysis of American Hospital Association (AHA) data 3

Gross Profit per Beneficiary GAO: 340B Covered Entities Earn High Oncology Profits in Medicare Program ONCOLOGY DRUG PROFITS IN MEDICARE, 340B-COVERED ENTITIES VS. NONCOVERED ENTITIES, 2013 Noncovered entities 340B-covered entities For 35 HCPCS codes, the beneficiary s 20% coinsurance exceeded the 340B covered entity s acquisition cost $11,130 $13,336 $9,238 $9,162 $5,749 $776 $902 $854 $764 $959 1 2 3 4 5 Cancer Drug Sources Pembroke Consulting analysis of Part B Payments For 340B-Purchased Drugs, OIG, November 2015. See New OIG Report Shows Hospitals Huge 340B Profits from Medicare-Paid Cancer Drugs, Drug Channels, December 2015 4

Percentage of oncology practices owned by a hospital or health system Vertical Integration of Cancer Care 60% Medicare Part B Payment Reform Expansion of 340B Program 50% 40% 30% 20% 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Source: Pembroke Consulting analysis of Evaluating The Role Of Payment Policy In Driving Vertical Integration In The Oncology Market, Health Affairs, April 2017 5

(thousands) For commercial payers, hospitals charge much more for provider-administered drugs than do physician offices MEDICAL BENEFIT SPENDING PER UNIT FOR OUTPATIENT SPECIALTY DRUGS, BY SITE OF CARE, 2015 Physician Office Hospital Outpatient Facility 2.2X 2.0X 1.7X 1.5X 2.3X $10.2 $9.7 $9.6 $8.4 $4.6 $4.1 $5.6 $6.4 $6.4 $2.8 Remicade Neulasta Perjeta Alimta Orencia Totals may not sum due to rounding. Figures show cost per claim in thousands. Source: Pembroke Consulting analysis of 2016 Medical Pharmacy Trend Report, Magellan Rx Management, 2017. See Latest Data Show That Hospitals Are Still Specialty Drug Profiteers, Drug Channels, April 2017 6

Number of locations The 340B Contract Pharmacy Boom 340B CONTRACT PHARMACY LOCATIONS, 2000-2017 20,000 18,000 16,000 14,000 12,000 10,000 8,000 6,000 4,000 2,000 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Data show number of unique contract pharmacy locations as of July of each year. Sources: Avalere Health (2000-2012); Pembroke Consulting analysis of OPA Daily Contract Pharmacy Database (2013-2017) See The Booming 340B Contract Pharmacy Profits of Walgreens, CVS, Rite Aid, and Walmart, Drug Channels, July 2017 7

Large Pharmacies Are Profiting from 340B Pricing 340B CONTRACT PHARMACY LOCATIONS, BY CHAIN, 2017 n = 19,868 pharmacy locations All Others 33% Walgreens 32% Albertsons 3% Kroger 5% Rite Aid 8% Walmart 9% CVS 10% 35% Source: Pembroke Consulting analysis of OPA Daily Contract Pharmacy Database (7/1/17). Company totals are computed from combined banners (store names) in the database. See The Booming 340B Contract Pharmacy Profits of Walgreens, CVS, Rite Aid, and Walmart, Drug Channels, July 2017 8

Retail Chains Expanding in 340B 6,367 CONTRACT PHARMACY LOCATIONS, BY CHAIN, 2013 VS. 2017 2013 2017 5,350 1,932 1,838 1,663 507 774 518 Change, 2013-2017 Walgreens CVS Walmart Rite Aid +19% +281% +137% +221% Source: Drug Channels Institute analysis of OPA Daily Contract Pharmacy Database (6/23/13; 7/1/17). Company totals are computed from combined banners (store names) in the database. 9

340B Contract Pharmacy Economics: Specialty Prescription No. Item Amount Computation Published List Prices [1] Wholesale Acquisition Cost (WAC) $5,000.00 Set by manufacturer [2] Average Wholesale Price (AWP) $6,000.00 [1] * 1.20 Pharmacy Revenue [3] Ingredient Cost Reimbursement $4,920.00 [2] * 82% (= AWP-18%) [4] Average Dispensing Fee $1.00 Payer survey data [5] Total Pharmacy Revenue $4,921.00 [3] + [4] 340B Entity Cost of Goods [6] Acquisition Cost to 340B Entity $0.01 Product with penny price [7] Fee to Split-Billing Vendor $10.00 Negotiated rate [8] Fee to Contract Pharmacy $803.00 [3] * 15% + $65 [9] Total Expense to 340B Entity $813.01 [6] + [7] + [8] 340B Entity Profit [10] Gross Profit per Prescription $4,107.99 [5] - [9] [11] Gross Margin per Prescription 83.5% [7] / [5] Source: Drug Channels Institute research and estimates. 10

Examples of 340B Contract Pharmacy Mega-Networks TOP TEN DISPROPORTIONATE SHARE HOSPITALS WITH THE LARGEST 340B CONTRACT PHARMACY NETWORKS, JULY 2017 Source: Drug Channels Institute analysis of OPA Daily Contract Pharmacy Database (7/1/17). See 10 Hospitals With 340B Contract Pharmacy Mega-Networks, Drug Channels, July 2017 Number of Contract Pharmacy Relationships Entity Walgreens CVS Rite Aid Walmart Kroger Albertsons Express Scripts OptumRx Other Total Henry Ford Hospital 91 171 20 8 50 0 11 6 79 436 Loyola University Medical Center 232 25 0 0 0 0 0 0 6 263 UCSF-Medical Center 113 25 9 0 0 63 8 0 18 236 Vanderbilt University Medical Center 97 33 0 39 33 0 7 0 19 228 The University Of Chicago Medical Center 206 10 0 0 0 0 0 0 0 216 Metrohealth Medical Center 66 25 12 16 0 0 6 0 70 195 University Of Miami Hospital 95 21 0 10 0 0 5 0 52 183 Froedtert Memorial Lutheran Hospital 122 18 0 0 12 0 11 5 13 181 University Of California Davis Medical Center 50 33 36 9 1 18 6 0 12 165 Rush University Medical Center 149 10 0 0 0 0 0 0 5 164 Top Ten Total 1,221 371 77 82 96 81 54 11 274 2,267 11

OIG: Hospitals do not always offer discounted 340B prices to uninsured patients at contract pharmacies 2 Does not offer discounted 340B price to uninsured patients* 10 Offers discounted 340B price to uninsured patients 13 5 Disproportionate Share Hospital (n=15) Community Health Center (n=15) * Includes 4 entities for which it was unclear whether their contract pharmacies offer the discounted 340B price to uninsured patients. Source: Pembroke Consulting analysis of Contract Pharmacy Arrangements in the 340B Program, Office of Inspector General, February 2014. See New OIG Report Confirms Our Worst Fears About 340B Contract Pharmacy Abuses, Drug Channels, February 2014. 12

340B Reduces Retail Generic Dispensing Rates GENERIC DISPENSING RATE AT WALGREENS PHARMACIES, BY THERAPEUTIC CLASS, 2012 All Prescriptions 340B Prescriptions 75% 70% 59% 48% 83% 68% 11% 19% 6% 25% Antivirals Anti-asthmatic and bronchodilator agents Antidiabetics Antihyperlipidemics Antihypertensives Source: Pembroke Consulting analysis of data in The 340B Discount Program: Outpatient Prescription Dispensing Patterns Through Contract Pharmacies In 2012. Health Affairs, 2014 See New Walgreens Data Verifies That 340B Reduces Retail Generic Dispensing Rates, Drug Channels, November 2014. 13

How the 340B Program Contributes to Higher Drug Costs Encourages a shift in site of care from lower-cost physician offices to higher-cost hospital outpatient settings Raises out-of-pocket costs for uninsured patients Lowers the generic dispensing rate Reduces manufacturers rebates to Medicare Part D and commercial payers Permits pharmacies and PBMs to profit from 340B discounts at the expense of needy and uninsured patients 14

General Resources Free industry updates from the Drug Channels blog (www.drugchannels.net) @DrugChannels Daily tweets about cool and intriguing stuff http://drugch.nl/wholesale http://drugch.nl/pharmacy 15